None
DE
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
['Globenewswire', 'Europe']
FinanzNachrichten.de: News
Second Quarter 2026 Financial ResultsAs of June 30, 2026, Milestone had cash, cash equivalents, and short-term investments of $170.6 million, compared to $106.0 million as of December 31, 2025.
Product revenues were $0.6 during the three months ended June 30, 2026.
For the six months ended June 30, 2026, product revenues were $0.8 million.
Research and development expense for the three months ended June 30, 2026, was $3.5 million, compared with $3.7 million for the prior year period.
Selling, general and administrative expense for the three months ended June 30, 2026, was $22.6 million, compared with $8.9 million for the prior year period.